$再生元制药(REGN)$ $罗氏控股(RHHBY)$ REGN预计H12022，Ronapreve在美国国内不会有营收，美国之外的话，罗氏说：We think we’ll have additional sales of Ronapreve in 2022 and longer-term it’s a little hard to call because it depends a lot on the trajectory of the pandemic.
| 发布于: | 雪球 | 转发：1 | 回复：1 | 喜欢：0 |
$再生元制药(REGN)$ $罗氏控股(RHHBY)$ REGN预计H12022，Ronapreve在美国国内不会有营收，美国之外的话，罗氏说：We think we’ll have additional sales of Ronapreve in 2022 and longer-term it’s a little hard to call because it depends a lot on the trajectory of the pandemic.
就当一次横财，然后全部用来回购股票了